Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2024-04-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于深圳华大基因股份有限公司向特定对象发行股票之持续督导保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" which translates to a "Continuous Supervision Sponsorship Summary Report" related to a specific stock issuance by Shenzhen BGI Genomics Co., Ltd. It details the sponsor's ongoing supervision work during the period after the issuance of shares to specific investors, including compliance with regulatory requirements, review of information disclosure, and use of raised funds. The document references regulatory approvals and audit reports but does not contain full financial statements or quarterly/yearly financial results. It is a summary report related to the sponsorship and supervision of a capital issuance, not a direct financial report or earnings release. Given the focus on sponsorship and supervision of a capital issuance, this fits best under the category of Capital/Financing Update (CAP). The document length is 2199 characters, which is relatively short but contains substantive content about the capital issuance supervision, not just an announcement or a certification. Therefore, the classification is CAP with high confidence.
2024-04-26 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司向特定对象发行股票之持续督导保荐总结报告书
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导定期现场检查报告" which translates to "2023 Annual Continuous Supervision Regular On-site Inspection Report" by CITIC Securities for Shenzhen BGI Genomics Co., Ltd. It contains detailed findings from an on-site inspection covering governance, internal control, information disclosure, protection of company interests, use of raised funds, and performance. The document includes detailed compliance checks, audit committee activities, and financial performance commentary. It is not a full annual report (10-K), nor an earnings release or call transcript. It is a detailed audit-related report focusing on compliance and internal controls, typical of an audit or regulatory inspection report. It is not a brief announcement or a proxy statement. The document is about the results of an inspection and internal control evaluation, which fits the category of Audit Report / Information (AR). The length and detail confirm it is the report itself, not just an announcement. Therefore, the classification is AR with high confidence. FY 2023
2024-04-25 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2023年度跟踪报告
Management Reports Classification · 95% confidence The document is titled as a "2023年度跟踪报告" (2023 Annual Tracking Report) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding 深圳华大基因股份有限公司 (Shenzhen BGI Genomics Co., Ltd.). It contains detailed information about the sponsor's review and supervision work, company governance, internal controls, fundraising supervision, and regulatory compliance issues during the year 2023. The document includes extensive discussion of regulatory inspections, compliance with disclosure requirements, and corrective measures taken. It is a comprehensive report on the sponsor's ongoing monitoring and oversight activities rather than a full annual report or financial statement. The document length is 9809 characters, which is substantial and contains substantive content rather than a brief announcement or certification. The nature of the document aligns with a Management Report or Sponsor's Tracking Report, which is best classified under Management Reports (MDA) as it provides detailed explanations of financial results, business trends, regulatory compliance, and outlook related to the company under sponsorship. It is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS) since it is a detailed sponsor tracking report with substantive content. Therefore, the appropriate classification is MDA with high confidence.
2024-04-25 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2023年度持续督导定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导定期现场检查报告" which translates to "2023 Annual Continuous Supervision Regular On-site Inspection Report" by CITIC Securities for Shenzhen BGI Genomics Co., Ltd. It contains detailed findings from an on-site inspection covering governance, internal control, information disclosure, protection of company interests, use of raised funds, and performance. The document includes detailed compliance checks, audit committee activities, and financial performance commentary. It is not a full annual report (10-K), nor a simple announcement. It is a detailed audit-related report focusing on regulatory compliance and internal controls, typical of an Audit Report / Information (AR). The length and content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2023
2024-04-25 Chinese
关于举行2023年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding the 2023 annual online earnings explanation meeting (业绩说明会) scheduled for April 18, 2024. It references that the 2023 annual report has already been disclosed on April 13, 2024, and invites investors to participate in the online meeting to discuss the company's performance. The document does not contain actual financial statements or detailed financial data but is an announcement of an event related to discussing the annual results. This fits the category of an Investor Presentation (IP) since it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings explanation meeting. The document length is short and it is not the report itself, nor a certification or voting result. Therefore, the best classification is Investor Presentation (IP).
2024-04-15 Chinese
关于2024年度公司及子公司向银行等金融机构申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the company's and its subsidiaries' application for a comprehensive credit facility from banks and financial institutions for the year 2024. It details the credit limits requested, the purpose of the credit, and the approval process including board and shareholder meetings. The document does not contain financial statements or detailed financial performance data but is an update on financing activities and credit arrangements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 1693 characters, which is consistent with an announcement rather than a full report.
2024-04-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.